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TDA consensus for urticaria 969as the sudden occurrence of wheals and/or angioedema for a period of  6 weeks. In addition,
the consensus attendees also approved the Urticaria Activity Score system or the Urticaria Ac-
tivity Score for 7 days system as the recommended method for assessing disease activity in
spontaneous urticaria.
Conclusion: It was also determined that the treatment goal for patients with any form of ur-
ticaria should be complete cessation of suffering from all urticaria symptoms. The recom-
mended treatment algorithms for chronic spontaneous urticaria and acute urticaria were
finally proposed and approved by 100% (19/19) and 84.2% (16/19) of the consensus attendees,
respectively.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
This report provides a detailed description of the devel-
opment process for the 2014 consensus of the Taiwanese
Dermatological Association (TDA) regarding the definition,
classification, diagnosis, and management of urticaria. The
TDA consensus was based, in large part, upon the 2013
urticaria guidelines produced jointly by the European
Academy of Allergy and Clinical Immunology (EAACI), the
EU-funded Network of Excellence, the Global Allergy and
Asthma European Network, the European Dermatology
Forum, and the World Allergy Organization and the 2014
urticaria guidelines published by the American Academy of
Allergy, Asthma & Immunology.1,2 The TDA consensus is
distinguished from those earlier guidelines primarily by its
inclusion of a number of amendments made specifically for
the sake of clinicians treating urticaria in Taiwan, and the
consensus thus serves as an important reference for der-
matologists throughout Taiwan.
A variety of original studies have investigated chronic
urticaria (CU) among patients in Taiwan. A recent study by
Lee et al,3 for example, sought to characterize the clinical
features of CU in Taiwan, and determined that although
atopy does not affect the severity or duration of CU, it is
associated with poor therapeutic responses to second-
generation antihistamines. Accordingly, the authors sug-
gest that taking a personal history of atopy, especially
allergic rhinitis, is of particular importance in managing the
symptoms of CU patients in Taiwan. In an earlier study
comparing CU patients to controls with athletes foot, Yang
et al4 found stress and insomnia to be among the most
important predisposing risk factors for CU among patients in
Taiwan. Other studies involving CU patients in Taiwan have
explored the efficacy of various treatments; for example, a
multicenter study by Fang et al5 confirmed the efficacy of
levocetirizine for the management of urticaria in Taiwanese
patients. In short, information from these and other
Taiwan-based studies, as well as personal clinical experi-
ences, was considered in addition to the aforementioned
international guidelines in arriving at the TDA consensus.
The information in the consensus was agreed upon by a
panel of national experts who convened at TDA urticaria
consensus meetings held on March 30, 2014 and May 17,
2014, with all the specific aspects of the content requiring
approval by at least 75% of the experts in attendance.Methods
Consensus panel
A total of 19 dermatologists with extensive experience in
urticaria management, recommended by their respective
teaching hospitals in Taiwan and the TDA itself, were
invited to and attended the TDA consensus meetings held
in Taipei, Taiwan. The 2013 EAACI/Global Allergy and
Asthma European Network/European Dermatology
Forum/World Allergy Organization and the 2014 American
Academy of Allergy, Asthma & Immunology urticaria
guidelines provided the foundations for the consensus
that the panel approved in the meeting, although a va-
riety of amendments made specifically for practitioners in
Taiwan were also considered. For each of these amend-
ments, discussions were conducted on the quality of sci-
entific evidence (including transparency and clear
criteria) supporting the given amendment, as well as
on the risks and benefits of the recommended
medications.6e8
Consensus voting system
The dermatologist experts attending the meeting cast their
votes for individual content items by rating their approval
of each item on a scale from 1 to 9, with 1 representing 0%
approval and 9 representing 100% approval. When ratings of
7e9 accounted for 75% of the total votes cast, the item in
question was deemed to have been approved. In the event
that the original version of an item was not approveddi.e.,
when ratings of 7e9 accounted for < 75% of all the vote-
sdpotential amendments to the item were drafted and
then voted upon. Votes on these amendments were con-
ducted on a yes/no basis, with an agreement rating of >
50% being required for implementation. If an amendment to
an item was approved, the amended item was then voted
on again using the 1e9 scale, with approval again contin-
gent upon ratings of 7e9 accounting for  75% of the votes.
When ratings of 7e9 for an amended item accounted for <
75% of the votes, or when “no” votes for an amendment
accounted for  50% of the votes, a different amendment
to the item was voted upon. In this way, each item was
approved either in its original form or in some amended
form.
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Definition of urticaria
The following definition was approved by 100% (19 out of
19) of the consensus meeting attendees.
Urticaria is characterized by the sudden appearance of
wheals (also known as hives), angioedema, or both.
A wheal typically exhibits the following three charac-
teristics: (1) initial presentation of a swelling of variable
size that is sometimes surrounded by a reflex erythema,
without epidermal change; (2) itching or, sometimes, a
tingling or burning sensation; and (3) a fleeting nature, with
the skin usually returning to its normal appearance within
24 hours.
Angioedema is characterized by the following features:
(1) a sudden, pronounced erythematous swelling or skin-
colored swelling of the lower dermis and subcutis, with
frequent involvement of the submucosa and (2) pain rather
than itching in some cases; the resolution of an angioedema
is slower than that of a wheal, and may take up to 72 hours.Classification of urticaria according to its
frequency, duration, and causes
A given case of urticaria can be classified as acute or
chronic on the basis of its duration, with acute urticaria
defined as the spontaneous occurrence of wheals, angioe-
dema, or both for a period of < 6 weeks, while CU is defined
as the sudden occurrence of wheals and/or angioedema for
a period of  6 weeks. Figure 1 presents an algorithm forFigure 1 Classification of subtypes of chronic urticaria (present
tendees, 84.2% (16/19) approved this figure. a For example, auto
bodies. b Also called urticaria factitia and dermographic urticari
urticaria. e Also called heat contact urticaria. Note. From “The EAA
diagnosis, and management of urticaria: the 2013 revision and up
Brzoza Z, Canonica GW, et al, 2014, Allergy, 69, p. 868e87. Copyrthe clinical classification of the acute and chronic forms, as
well as for the various CU subtypes, and includes footnotes
providing additional information regarding causes and
alternative names for several subtypes.
Assessment of disease activity using the Urticaria
Activity Score
In both clinical care and medical trials, the Urticaria Ac-
tivity Score (UAS) system, a simple scoring system proposed
in previous guidelines and since validated in a study by
Młynek et al,9 is the recommended method for assessing
disease activity in spontaneous urticaria. More specifically,
the Urticaria Activity Score for 7 days (UAS7) is the standard
used by the EAACI for such evaluations (Figure 2). The UAS
provides two distinct advantages: (1) due to widespread
adaptation, the use of the UAS allows for a direct com-
parison of study and results from various researchers
worldwide, and (2) the UAS is based on the patient’s own
assessment of the key symptoms such as wheals and pru-
ritus, and this self-assessment is particularly valuable
because the intensity of urticaria symptoms changes often,
such that 24-hour self-evaluation scores taken once daily by
the patient for several days provide the best picture of
overall disease activity.
Diagnosis
In recent years, substantial progress has been achieved in
identifying the causes of different types and subtypes of
urticaria. For example, Zuberbier and Maurer10 haveing with wheals, angioedema, or both). Of the consensus at-
reactivity, i.e., the presence of mast cell-activating autoanti-
a. c Also called cold contact urticaria. d Also called pressure
CI/GA2LEN/EDF/WAO guideline for the definition, classification,
date,” by Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C,
ight 2014. John Wiley & Sons A/S. Adapted with permission.
Figure 2 The UAS/UAS7 for assessing disease activity in CSU. Of the consensus attendees, 78.9% (15/19) approved this figure.
Sum of scores: 0e6 for each day is summarized over 1 week (maximum 42). UAS is a diary-based, combined score of severity of itch
and number of wheals (scale 0e6). CSUZ chronic spontaneous urticaria; UASZ Urticaria Activity Score; UAS7Z Urticaria Activity
Score for 7 days. Note. From “The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management
of urticaria: the 2013 revision and update,” by Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al,
2014, Allergy, 69, p. 868e87. Copyright 2014. John Wiley & Sons A/S. Adapted with permission.
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pertaining to chronic spontaneous urticaria (CSU). The
studies in question, however, have reported considerable
variation in the frequency of the various underlying causes,
differences that are likely to be the results, to some extent
at least, of regional differences around the world, such as
differences in the traditional diets of different regions and
differing prevalence rates for various infections. As such, it
is important for clinicians to bear in mind that it is not
necessary to identify and investigate all the possible caus-
ative factors in all patients.
Patient history
Without necessarily aiming to identify all the potential
causative factors, the first step in making an accurate
diagnosis is taking a thorough patient history. Patients
should be questioned regarding all the following points.
Characteristics. The following list of characteristics was
approved by 100% (19/19) of the consensus meeting at-
tendees: (1) time of onset of disease; (2) frequency/dura-
tion; (3) diurnal variation; (4) occurrence in relation to
weekends, holidays, seasons, and foreign travels; (5)
shape, size, and distribution of wheals; (6) associated
angioedema; and (7) associated subjective symptoms of
lesions, e.g., itch and pain.
History. The following list of relevant history items was
approved by 100% (19/19) of the consensus meeting at-
tendees: (1) family and personal history regarding urticaria
and atopy; (2) previous or current allergies, infections, in-
ternal diseases, or other possible causes; (3) psychosomatic
and psychiatric diseases; (4) relationship to the menstrualcycle; (5) smoking habits (especially, the use of perfumed
tobacco products); (6) type of work; (7) hobbies; (8) stress
(eustress and distress); (9) previous therapy and response to
therapy; and (10) previous diagnostic procedures/results.
Possible factors for wheals. (1) Gastric/intestinal prob-
lems; (2) induction by physical agents or exercise; (3) use of
drugs [e.g., nonsteroidal anti-inflammatory drugs, in-
jections, immunizations, hormones, laxatives, supposi-
tories, ear and eye drops and alternative remedies (Chinese
herbs)], recreational drugs, and local anesthesia; (4)
observed correlation to food and alcohol-containing bev-
erages; and (5) surgical implantations and events during
surgery.
Quality of life. Quality of life related to urticaria and
emotional impact.
(Note: the abovementioned “possible factors for
wheals” and “quality of life” items were approved by 78.9%
(15/19) of the attendees.)
The second step of the diagnosis is a physical examina-
tion of the patient. When indicated by the patient history,
this should include diagnostic provocation tests including
drug, food, and physical tests. That being said, intensive
and costly general screening programs for causes of urti-
caria are not recommended for most cases. Figure 3 shows
the recommended diagnosis algorithm for urticaria, while
Table 1 specifies the recommended diagnostic tests for
frequent urticaria subtypes.
Clinical management of urticaria
Treatment goal. As noted above, the EAACI guidelines
recommend using a patient’s UAS7 score as a simple and
Figure 3 Recommended diagnosis algorithm for urticaria. Diagnostic algorithm for patients presenting with wheals, angioedema,
or both. All the consensus attendees (100%; 19/19) approved this figure. a Autoinflammatory diseases are the result of uncontrolled
activation of the innate immune system including Schnitzler syndrome, systemic juvenile idiopathic arthritis, cryopyrin-associated
periodic syndromes, etc. 1 Other (new) drugs may also induce bradykinin-mediated angioedema. 2 Patients should be asked for a
detailed family history and age of disease onset. 3 Test for elevated inflammation markers (C-reactive protein, erythrocyte
sedimentation rate), test for paraproteinemia in adults, look for signs of neutrophil-rich infiltrates in skin biopsy; perform gene
mutation analysis of hereditary periodic fever syndromes (e.g., cryopyrin-associated periodic syndrome), if strongly suspected. 4
Patients should be asked: ‘How long do your wheals last?’ 5 Test for Complement C4, C1-INH levels and function; in addition, test
for C1q and C1-INH antibodies, if AAE is suspected; perform gene mutation analysis, if former tests are unremarkable but patient’s
history suggests hereditary angioedema. 6 Wait for up to 6 months for remission; additional diagnostics to test for C1-inhibitor
deficiency should only be performed if the family history suggests hereditary angioedema. 7 Does the biopsy of lesional skin
show damage of the small vessels in the papillary and reticular dermis and/or fibrinoid deposits in perivascular and interstitial
locations suggestive of UV (urticarial vasculitis)? 8 Patients should be asked: ‘Can you make your wheals come?’ 9 In patients with a
history suggestive of inducible urticaria, standardized provocation testing according to international consensus recommendations
should be performed. 10 Acquired AIDs include Schnitzler’s syndrome as well as systemic-onset juvenile idiopathic arthritis and
adult-onset Still’s disease; hereditary AIDs include cryopyrin-associated periodic syndromes such as familial cold autoinflammatory
syndromes, MuckleeWells syndrome, and neonatal-onset multisystem inflammatory disease, more rarely hyper-IgD syndrome and
tumor necrosis factor receptor alpha-associated periodic syndrome. 11 In some rare cases, recurrent angioedema is neither mast
cell mediator mediated nor bradykinin mediated, and the underlying pathomechanisms remain unknown. These rare cases are
referred to as “idiopathic angioedema” by some authors. AAE Z acquired angioedema due to C1 inhibitor deficiency; ACE-
INH Z angiotensin-converting enzyme inhibitor; AE Z angioedema; AH Z antihistamine; AID Z autoinflammatory disease;
HAE Z hereditary angioedema; IL-1 Z interleukin-1. Note. From “The EAACI/GA2LEN/EDF/WAO guideline for the definition,
classification, diagnosis, and management of urticaria: the 2013 revision and update,” by Zuberbier T, Aberer W, Asero R, Bindslev-
Jensen C, Brzoza Z, Canonica GW, et al, 2014, Allergy, 69, p. 868e87. Copyright 2014. John Wiley & Sons A/S. Adapted with
permission.
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Moreover, the same guidelines also indicate that complete
symptom relief should be the goal of treatment. In the TDA
consensus meeting, this stated treatment goal of the EAACI
guidelines was a topic of some discussion. Specifically, it
was noted that only around 40% of patients can achieve a
UAS7 score of 0, which would indicate complete symptom
relief. In contrast, approximately 80% of patients can reach
a UAS7 score of < 5, which is also a substantial improve-
ment in most cases. Accordingly, attendees at the TDA
consensus meetings raised the question of whether thetreatment goal should be complete relief from all symp-
toms or whether a UAS7 score of  5 could be deemed
sufficient as the goal of treatment. After some discussion, it
was ultimately decided that complete symptom relief
should be the treatment goal, but that the UAS7 score or
response to a medication should also be used to determine
whether the given treatment is effective. Along the same
lines, it is worth noting that different patients, different
illnesses, and different guidelines may have differing
treatment goals (e.g., a patient may find it acceptable that
symptoms are relieved simply to the extent that these are
Table 1 Recommended diagnostic tests in frequent urticaria subtypes.a,11e22.
Types Subtypes Routine diagnostic tests
(recommended)
Extended diagnostic programb (suggested
based on history only) to identify eliciting
factors & rule out possible differential
diagnoses if indicated
Spontaneous urticaria Acute spontaneous
urticaria
None Nonec
Chronic spontaneous
urticaria
Differential blood count &
ESR or CRP
Omission of suspected drugs
(e.g., NSAIDs)
(1) Thyroid hormones & Copyright 2013.
Name of Copyright Holder. Reprinted
with permission. autoantibodies
(2) Autologous serum skin test or basophil
activation test
(3) Type I allergy (IgE, MAST, CAP)
(4) Functional autoantibodies (ANA, etc.)
(5) Infectious diseases (e.g., Helicobacter
pylori)
(6) Lesional skin biopsy
(7) Skin tests including physical tests
(8) Tryptased
(9) Pseudoallergen-free diet for 3 wk
Inducible urticaria Cold urticaria Cold provocation &
threshold test (ice cube,
cold water, cold wind)
Differential blood count & ESR/CRP
cryoproteins rule out other diseases,
especially infections
Delayed pressure
urticaria
Pressure test None
Heat urticaria Heat provocation &
threshold test
None
Solar urticaria UV & visible light of
different wavelengths &
threshold test
Other light-induced dermatoses ruled out
Symptomatic
dermographism
Elicit dermographism &
threshold test
(dermographometer)
Differential blood count, ESR/CRP
Vibratory angioedema Test with vortex None
Aquagenic urticaria Wet cloths at body
temperature applied for
20 min
None
Inducible urticaria Cholinergic urticaria Exercise & hot bath
provocation
None
Contact urticaria Cutaneous provocation test.
Skin tests with immediate
readings, e.g., prick test,
prick-by-prick test, patch
test
None
ANA Z antinuclear antibodies; CAP Z Phadia Immunocap (Phadia CAP) allergen-specific IgE test; CRP Z C-reactive protein;
ESR Z erythrocyte sedimentation rate; IgE Z immunoglobulin E; MAST Z Multiple-allergen simultaneous test; NSAID Z nonsteroidal
anti-inflammatory drug.
Note. From “The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013
revision and update” by Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al, 2014, Allergy 69, p. 868e87.
Copyright 2014. John Wiley & Sons A/S. Adapted with permission.
a Of the consensus attendees, 89.5% (17/19) approved this table.
b Depending on the suspected cause.
c Unless strongly suggested by patient history, e.g., allergy.
d As an indication of severe systemic disease.
TDA consensus for urticaria 973tolerable and quality of life, in turn, is improved). With
respect to CU, however, it is believed that no patient would
be willing to take medication every day and still suffer from
urticaria symptoms. Therefore, with the aforementioned
caveats in mind, it was decided that the treatment goal forpatients with any form of urticaria should be complete
cessation of suffering from all urticaria symptoms.
To the above end, Figure 4 shows the recommended
treatment algorithm for CSU, including tracks for both
nondrug and pharmacologic therapies. The figure also
Figure 4 Recommended treatment algorithm for chronic spontaneous urticaria.23e39 Please note that the listed order of the
third-line treatments does not reflect preference. All the consensus attendees (100%; 19/19) approved this figure after discussions
and amendments for each item. First line Z high-quality evidence: low cost and worldwide availability (e.g., modern second-
generation antihistamines also exist in developing countries, mostly cheaper than old sedating antihistamines), per daily dose
as the half-life time is much longer, very good safety profile, good efficacy. Second line Z high-quality evidence: low cost, good
safety profile, good efficacy. Third line as an add-on to AH. Cyclosporine A Z high-quality evidence: medium to high cost,
moderate safety profile, good efficacy. Omalizumab Z high-quality evidence: high cost, very good safety profile, very good ef-
ficacy. Montelukast Z low-quality evidence: low cost, good safety, low efficacy. Short course of corticosteroids Z low-quality
evidence: low cost, worldwide availability, good safety profile (for short course only), good efficacy during intake, but very low for
lasting efficacy. a H1 antihistamines and omalizumab are the licensed treatments for CSU (FDA/EMA). b Refer to Table S1 for
approved age. ACEi Z angiotensin-converting enzyme inhibitor; AH Z antihistamine; CSU Z chronic spontaneous urticaria;
FDAZ US Food and Drug Administration; MEAZ European Medicines Agency; NSAIDZ nonsteroidal anti-inflammatory drug. Note.
From “The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013
revision and update,” by Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al, 2014, Allergy, 69, p.
868e87. Copyright 2014. John Wiley & Sons A/S. Adapted with permission.
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that can potentially aggravate urticaria and should thus be
minimized or avoided. Table 2 provides a list of alternative
anti-inflammatory agents that can be considered for use in
certain cases of CU, including information from the EAACIurticaria guideline regarding the degree of research evi-
dence for each agent and the strength of the corresponding
EAACI recommendation; British Society for Allergy and
Clinical Immunology grades and indications for the agents
are likewise included.
Table 2 Alternative anti-inflammatory agents for specific chronic urticaria indications.a
Alternative
treatment
EAACI
evidence
EAACI
recommendation
BSACI
grade
BSACI Specific indication/
comments
Side effects
Methotrexate Very low Weak D (rare) Beneficial for
corticosteroid-dependent
chronic idiopathic urticaria
(2 patients); efficacy in
urticarial vasculitis
(1 patient)
Loss of appetite; nausea;
vomiting; abdominal pain;
impaired digestion; dyspepsia;
inflammation & ulceration in
mouth & throat; increase in
level of liver enzyme; herpes
zoster; effects on the blood,
e.g., anemia, leukopenia, &
thrombocytopenia; diarrhea;
dry cough; shortness of breath;
chest pain; fever; rashes;
redness & itching; headache;
tiredness; drowsiness
Hydroxychloroquine Very low Weak Not
specified
Improvement of QoL, but no
reduction in urticaria scores
or medication requirements
Feeling or being sick, loss of
appetite, dizziness, ringing in
the ears, headache, mood
swings, fits, spasm of airways,
muscle weakness, decreased
reflexes, low platelets, bone
marrow depression, abnormal
nerve conduction, abnormal
liver function, seen on blood
tests, lowering of the blood
glucose level, diarrhea,
stomach pain, visual
disturbances, vertigo, hearing
loss, nervousness, psychosis,
liver failure, itchy & raised
rashes, muscle wasting,
anemia, low white blood cells,
general tissue swelling,
problems with heart,
conduction system, bleaching
of hair/hair loss
Dapsone Very low Weak D (rare) Several single case reports
of successful treatment of
urticarial vasculitis in
resistant cases; helped 1
patient with autoimmune
thyroiditis to stop oral
steroid treatment
Back, leg, or stomach pain;
bluish fingernails, lips, or skin;
difficult breathing; fever; loss
of appetite; pale skin; skin
rash; unusual tiredness or
weakness
Colchicine Ineffective d D (rare) One patient showed total
clearance of urticarial
vasculitic rashes & chronic
vasculitic ulceration after
previously being
unresponsive to steroids in
combination with dapsone &
HCQ
Diarrhea, nausea or vomiting,
stomach pain
Azathioprine Less evidence
available
d d d Black, tarry stools; bleeding
gums; blood in urine or stools;
chest pain; cough or
hoarseness; fever or chills;
lower back or side pain; painful
or difficult urination; pinpoint
red spots on the skin; shortness
of breath; sore throat; sores,
(continued on next page)
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Table 2 (continued )
Alternative
treatment
EAACI
evidence
EAACI
recommendation
BSACI
grade
BSACI Specific indication/
comments
Side effects
ulcers, or white spots on the
lips or in the mouth; swollen
glands; unusual bleeding or
bruising; unusual tiredness or
weakness
Ketotifen Low Weak d d Chills, cough, diarrhea, fever,
general feeling of discomfort or
illness, headache, joint pain,
loss of appetite, muscle aches
& pains, nausea, runny nose,
shivering, sore throat,
sweating, trouble sleeping,
unusual tiredness or weakness,
vomiting
BSACIZ British Society for Allergy and Clinical Immunology; EAACI Z European Academy of Allergy and Clinical Immunology;
HCQ Z hydroxychloroquine; QoL Z quality of life.
a Of the consensus attendees, 89.5% (17/19) approved this table.
976 W.-H. Chung et al.Meanwhile, it is important to note that the 2013 EAACI
urticaria guideline addresses acute urticaria and CU simul-
taneously, always recommending the use of H1 antihista-
mines. In order to provide additional information,
therefore, the TDA consensus meetings sought to establish
a recommended treatment algorithm specifically designed
for acute urticaria. The resulting treatment algorithm is
shown in Figure 5, and includes specific information on
when to prescribe epinephrine, systemic steroids, and H1
and H2 antihistamines. For example, it is recommended
that epinephrine should be used as the third-line treatment
(after H1 and H2 antihistamines and systemic steroids) for
severe angioedema or as the first-line treatment should the
patient present with serious respiratory, cardiac, or
gastrointestinal symptoms.Figure 5 Recommended treatment algorithm for acute ur-
ticaria. Of the consensus attendees, 84.2% (16/19) approved
this figure. a Refer to Table S1 for approved age. Note. From
“The EAACI/GA2LEN/EDF/WAO guideline for the definition,
classification, diagnosis, and management of urticaria: the
2013 revision and update,” by Zuberbier T, Aberer W, Asero R,
Bindslev-Jensen C, Brzoza Z, Canonica GW, et al, 2014, Allergy,
69, p. 868e87. Copyright 2014. John Wiley & Sons A/S. Adapted
with permission.With regard to the algorithm recommended in Figure 4,
it should be noted that the time between each line of de-
fense was shortened from the original EAACI guidelines
upon which the TDA consensus is based. It may thus take
longer than the time intervals listed for any medication’s
effectiveness to become evident. As such, it is recom-
mended that physicians move to the next line only when a
given medication or a combination of medications has no
effect. It is also worth noting that not all dermatologists
will agree on the placement of certain drugs in these lines
of defense; however, all options must be made available.
Drugs listed in these guidelines are listed in order of pref-
erence, but it is still considered permissible within these
guidelines for physicians to skip certain drugs. Please also
be aware that some of the drugs have been added to the
guidelines on the basis of clinical evidences or experiences
provided by Taiwanese dermatologists, rather than on the
basis of published evidence from clinical trials. In addition,
please bear in mind that when adding first or second anti-
histamines in the second line of defense, it is also common
to increase the dosage, and for this reason, the qualifier “as
tolerated” has been added in these guidelines. Clinicians
should also be aware that H1 antihistamines and omalizu-
mab are the only medications licensed for treating CU by
the US Food and Drug Administration and European Medi-
cines Agency. It was also determined that the treatment
goal for patients with any form of urticaria should be
complete cessation of suffering from all urticaria symp-
toms. However, titration of H1 antihistamines was not
included in this consensus.
As made clear by the above discussion, although the TDA
consensus was largely based on the EAACI guidelines and
other previously published guidelines, this consensus differs
from those guidelines with regard to a number of details.
These differences, a number of which are listed in Table 3,
were based, to varying degrees, on research studies con-
ducted in Taiwan as well as on the clinical experiences of
the consensus experts in treating patients in Taiwan.
Table 3 Treatment algorithms of the AAAAI, EAACI, and TDA guidelines.
Treatment
algorithm
Guidelines
AAAAI EAACI TDAa
1st line  Second-generation
H1 antihistamine
 Avoidance of triggers
(e.g., NSAIDs) &
relevant physical
factors if physical
urticaria/angioedema
syndrome is present
Second-generation
H1 antihistamine
Second-generation H1
antihistamine
2nd line 1 or more of the following:
 Dose advancement of
2nd-generation
antihistamine used in
the 1st line
 Addition of another
2nd-generation antihistamine
 Addition of an H2-antagonist
 Addition of a leukotriene
receptor antagonist
 Addition of the 1st-generation
antihistamine to be taken
at bedtime
Up to 4 licensed
dose of H1 antihistamine
1 or more of the following:
 Up to 4 licensed dose of
2nd-generation H1 used in
the 1st line
 Addition of another
2nd-generation antihistamine
 Addition of a 1st-generation
antihistamine or sedative
antihistamines as tolerated
 Addition of an H2 antihistamine
 Addition of autologous whole
blood injection
If symptoms persist after
further 1e2 wk, change to
another 2nd line/combination
of the above 2nd line
 Exacerbation: systemic
steroid (maximum 10 d
within 1 mo)
3rd line Dose advancement of potent
antihistamine as tolerated
 Addition of omalizumab,
cyclosporine A or montelukast
 Exacerbation: systemic
steroid (3e7 d)
Addition of an alternative
agent:
 Omalizumab
 Cyclosporine
 Leukotriene receptor
antagonist
 Other anti-inflammatory
agents
4th line Addition of an alternative agent:
 Omalizumab or cyclosporine
Other anti-inflammatory
agents, immunosuppressants,
or biologics
N/A N/A
Symptom
persistence
N/A  Between 1st & 2nd lines: 2 wk
 Between 2nd &
3rd lines: 1e4 wk
 Between 1st & 2nd lines: 1e2 wk
 Between 2nd & 3rd lines: 4e6 wk
Renal & hepatic
impairment
N/A N/A Dose adjustment may be
needed for patients with impaired
renal or hepatic function
AAAAI Z American Academy of Allergy, Asthma & Immunology; EAACI Z European Academy of Allergy and Clinical Immunology;
NSAID Z nonsteroidal anti-inflammatory drug; N/A Z not available; TDA Z Taiwanese Dermatological Association.
a Unique aspects of the TDA guidelines are highlighted in bold type.
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Figure 6 Recommended treatment algorithm for CSU in
children under the age of 12 years. All the consensus attendees
(100%; 19/19) approved this figure. a Refer to Table S1 for
approved age. CSU Z chronic spontaneous urticaria. Note.
From “The EAACI/GA2LEN/EDF/WAO guideline for the defini-
tion, classification, diagnosis, and management of urticaria:
the 2013 revision and update,” by Zuberbier T, Aberer W, Asero
R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al, 2014, Al-
lergy, 69, p. 868e87. Copyright 2014. John Wiley & Sons A/S.
Adapted with permission.
Figure 7 Recommended treatment algorithm for CSU in
pregnant women. All the consensus attendees (100%; 19/19)
approved this figure. a H1 antihistamines and omalizumab are
the licensed treatments for CSU (FDA/EMA). b Refer to Table S1
for approved age and use in special populations. CSUZ chronic
spontaneous urticaria; FDAZ US Food and Drug Administra-
tion; MEA Z European Medicines Agency. Note. From “The
EAACI/GA2LEN/EDF/WAO guideline for the definition, classifi-
cation, diagnosis, and management of urticaria: the 2013
revision and update,” by Zuberbier T, Aberer W, Asero R,
Bindslev-Jensen C, Brzoza Z, Canonica GW, et al, 2014, Allergy,
69, p. 868e87. Copyright 2014. John Wiley & Sons A/S. Adapted
with permission.
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Elderly patients. In general, dose selection for elderly pa-
tients should be considered carefully due to possible drug
interactions or adverse effects, such as urinary retention,
dry mouth, glaucoma, and central nervous system effects.
In addition, the risk of patient falls or traffic accidents
should be taken into consideration when prescribing anti-
histamines. On balance, the use of medications for CSU in
elderly patients may be considered when the potential
benefits outweigh the potential risks to the patient.
Patients with renal or hepatic impairment. Dose
adjustment may be needed for patients with impaired renal
or hepatic function. Dose adjustment should also be
considered for patients receiving dialysis (whether hemo-
dialysis or peritoneal dialysis). Please refer to Table S1 for
specific recommendations regarding the use of individual
medications for patients with renal or hepatic impairment.
Children under the age of 12 years and pregnant
women. Figures 6 and 7 present the recommended treat-
ment algorithms for children under the age of 12 years and
pregnant women, respectively. With regard to children, a
general recommendation is that only those medications
that have been proved by past researches to be safe and
effective in the pediatric population should be used. For
this reason, cetirizine, desloratadine, fexofenadine, levo-
cetirizine, and loratadine are among the recommended
medications for treating patients under the age of 12 years,
as all these medications have been well studied in pediatric
populations, with the long-term safety of each having been
well established.40,41
In principle, the same considerations should apply to the
treatment of pregnant women. As a general rule, consid-
ering the potential risks and benefits, prescribing clinicians
should avoid the use of any systemic treatment in pregnant
women, especially during the first trimester. At the same
time, pregnant women also have a right to receive the best
therapy possible, and although systematic studies regarding
the safety of treatments for pregnant women with urticaria
have yet to be carried out, it is also worth noting that no
studies have been conducted regarding the possible nega-
tive effects of increased levels of histamine occurring in
urticaria treatment during pregnancy. Furthermore,
because a number of the modern second-generation anti-
histamines are now available for purchase without a pre-
scription and have thus been used widely in treating both
allergic rhinitis and urticaria, it can be assumed that many
pregnant women have used these drugs, especially during
the earliest stages of pregnancy (i.e., before they were
aware that they were pregnant); however, there have been
no widespread reports of problems occurring as a result of
this widespread usage. Nonetheless, maintaining the high-
est safety is of paramount importance during pregnancy,
and prescribing clinicians should carefully adhere to the
consensus guidelines accordingly.
Breastfeeding women: If used by a nursing mother, low
concentrations of all H1 antihistamines will be excreted in
the mother’s breast milk. Furthermore, nursing infants
have been known to occasionally become sedated after
ingesting old first-generation H1 antihistamines transmitted
in breast milk. For this reason, the use of second-generation H1 antihistamines is typically considered pref-
erable for nursing mothers. As a general rule, the risk-to-
benefit ratio for use of these drugs in breastfeeding
women should be considered on a case-by-case basis, and
when a satisfactory balance is indicated between the risks
and benefitsdi.e., when the potential benefits to the
mother in terms of urticaria relief outweigh any possible
TDA consensus for urticaria 979risks to the infant that may result from transmission of the
drug in the mother’s milkdthen the use of the medication
under consideration will generally be considered accept-
able. That being said, all prescribing decisions should be re-
evaluated, as necessary, according to the most current
recommendations provided by the relevant regulatory au-
thorities. Please refer to Table S1 for specific recommen-
dations regarding the use of individual medications in
breastfeeding women.
Conclusion
By means of the current consensus, the TDA has updated
the most recent information on urticaria, with a special
emphasis on Taiwan, in order to provide doctors and pa-
tients with an optimal care model and to increase the
quality of urticaria care. Moreover, future research efforts
into a variety of relevant topics, including, but not limited
to, the global epidemiology of urticaria in adults and chil-
dren, social and economic consequences of urticaria, and
identification of new biological markers for urticaria,
should allow for further refinement of treatment guidelines
and, in turn, increased care quality in the future.
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